Morand E, Pike M, Merrill JT et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2023 Feb;75(2):242-252. doi: 10.1002/art.42391. Epub 2022 Nov 11
Felten R, Dervovic E, Chasset F et al. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. Autoimmun Rev. 2018 Aug;17(8):781-790.
Seif F, Khoshmirsafa M, Aazami H et al The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017 Jun 21;15(1):23.
Burke JR, Cheng L, Gillooly KM et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019 Jul 24;11(502):eaaw1736.
Armstrong AW, Gooderham M, Warren RB et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88(1):29-39.
Mease PJ, Deodhar AA, van der Heijde D et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 Jun;81(6):815-822.
Morand EF, Vital EM, Petri M et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023 Mar 25;401(10381):1001-1010.
Petri M, Bruce IN, Dörner T et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023 Mar 25;401(10381):1011-1019.
Catlett IM, Aras U, Hansen L et al. First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin Transl Sci. 2023 Jan;16(1):151-164.
Felten R, Scherlinger M, Mertz P et al. New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review. Joint Bone Spine. 2023 Mar;90(2):105523.
Petri M et al. Arthritis Rheum. 2012 Aug;64(8):2677-86.
Gladman DD et al. J Rheumatol. 2002 Feb;29(2):288-91.
Yee CS et al. Arthritis Rheum. 2006 Oct;54(10):3300-5.
Furie RA et al. Arthritis Rheum. 2009 Sep 15;61(9):1143-51.
Wallace DJ et al. Ann Rheum Dis. 2014 Jan;73(1):183-90.
GOLDER, Vera, et al. The Lancet Rheumatology, 2019, 1.2: e95-e102.
Albrecht J et al. J Invest Dermatol. 2005 Nov;125(5):889-94.
Morand, Eric F et al.The Lancet Rheumatology, Volume 4, Issue 4, e282 - e292
Richard A, Eric F , Ian N et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial,The Lancet Rheumatology,Volume 1, Issue 4,2019,Pages e208-e219.
